Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Accured Expenses: 2012-2025

Historic Change in Accured Expenses for CorMedix (CRMD) over the last 9 years, with Sep 2025 value amounting to $54.7 million.

  • CorMedix's Change in Accured Expenses rose 484.49% to $54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.5 million, marking a year-over-year increase of 791.75%. This contributed to the annual value of $23.0 million for FY2024, which is 667.41% up from last year.
  • According to the latest figures from Q3 2025, CorMedix's Change in Accured Expenses is $54.7 million, which was up 932.90% from -$6.6 million recorded in Q2 2025.
  • CorMedix's 5-year Change in Accured Expenses high stood at $54.7 million for Q3 2025, and its period low was -$6.6 million during Q2 2025.
  • Over the past 3 years, CorMedix's median Change in Accured Expenses value was $693,026 (recorded in 2024), while the average stood at $8.8 million.
  • In the last 5 years, CorMedix's Change in Accured Expenses soared by 632.32% in 2021 and then plummeted by 723.09% in 2025.
  • Over the past 5 years, CorMedix's Change in Accured Expenses (Quarterly) stood at $2.1 million in 2021, then plummeted by 62.39% to $807,375 in 2022, then slumped by 251.61% to -$884,872 in 2023, then tumbled by 173.00% to $15.0 million in 2024, then surged by 484.49% to $54.7 million in 2025.
  • Its last three reported values are $54.7 million in Q3 2025, -$6.6 million for Q2 2025, and $331,443 during Q1 2025.